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Non-enzymatic chemistry enables
2-hydroxyglutarate-mediated activation
of 2-oxoglutarate oxygenases
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Accumulation of (R)-2-hydroxyglutarate in cells results from mutations to isocitrate
dehydrogenase that correlate with cancer. A recent study reports that (R)-, but not
(S)-2-hydroxyglutarate, acts as a co-substrate for the hypoxia-inducible factor prolyl
hydroxylases via enzyme-catalysed oxidation to 2-oxoglutarate. Here we investigate the
mechanism of 2-hydroxyglutarate-enabled activation of 2-oxoglutarate oxygenases, including
prolyl hydroxylase domain 2, the most important human prolyl hydroxylase isoform. We
observe that 2-hydroxyglutarate-enabled catalysis by prolyl hydroxylase domain 2 is not
enantiomer-specific and is stimulated by ferrous/ferric ion and reducing agents including
L-ascorbate. The results reveal that 2-hydroxyglutarate is oxidized to 2-oxoglutarate
non-enzymatically, likely via iron-mediated Fenton-chemistry, at levels supporting in vitro
catalysis by 2-oxoglutarate oxygenases. Succinic semialdehyde and succinate are also
identified as products of 2-hydroxyglutarate oxidation. Overall, the results rationalize the
reported effects of 2-hydroxyglutarate on catalysis by prolyl hydroxylases in vitro and suggest
that non-enzymatic 2-hydroxyglutarate oxidation may be of biological interest.
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M
utations to genes encoding for enzymes of the
tricarboxylic acid (TCA) cycle, including isocitrate
dehydrogenase (IDH1/2), can lead to substantial
increases in cellular metabolites, as observed in both genetic
diseases (germline mutations)1 and in cancer (somatic muta-
tions)2. Elevated levels of (R)-2-hydroxyglutarate ((R)-2HG)
produced by a ‘gain-of-function’ mutation to IDH1/2 result in
massively increased concentrations of (R)-2HG (up to 10mM)
and decreases in 2-oxoglutarate (2OG) levels3. It is proposed that
elevated levels of succinate, fumarate and (R)-2HG in humans
cause pro-oncogenic effects via inhibition of Fe(II)/2OG
dependent oxygenases4–6. 2OG oxygenases are involved in
chromatin regulation by modification of both nucleic acids, for
example 5-methylcytosine oxidation, and histone tails via
Ne-methyl lysine residue demethylation7. 2OG oxygenases also
play pivotal roles in the cellular and physiological responses
to hypoxia by regulation of the levels and activity of the
hypoxia-inducible transcription factor (HIF), which is an
a,b-heterodimeric protein that activates transcription of an
array of genes under conditions of low oxygen availability8.
The prolyl hydroxylase domain enzymes (PHDs, EGLN 1-3)
catalyse hydroxylation of prolyl-residues in HIF-a isoforms, a
post-translational modification that signals for the proteosomal
degradation of HIF-a9. Factor inhibiting HIF (FIH) catalyses
hydroxylation of an asparaginyl-residue resulting in reduction of
HIF-a mediated transcription by reducing binding of HIF to
transcriptional co-activators9. HIF upregulation activates the
transcription of a gene array, which is proposed to promote
tumour growth via increased angiogenesis. It is therefore
proposed that inhibition of HIF hydroxylases by TCA
cycle metabolites and (R)-2HG may be linked to tumour
development10. It has been reported that elevated (R)-2HG
levels caused by IDH mutations may indeed inhibit PHD action
in cells resulting in HIF-activated transcription11, though our
work and that of others has indicated that (R)- and (S)-2HG are
only weak inhibitors for the HIF hydroxylases12–14. It is also
possible that elevated (R)-2HG concentrations inhibit chromatin-
modifying 2OG oxygenases15,16.
Although it has been widely perceived that HIF is an
oncoprotein, HIF-a isoforms can act as tumour suppressors in
certain tumours17–20. Thus, PHD inhibition may be of
therapeutic interest for such cancers. In contrast to the
paradigm that TCA cycle metabolite and (R)-2HG-mediated
inhibition of 2OG dependent oxygenases is pathogenic, it has
been recently reported that (R)-, but not (S)-2HG, actually
stimulates PHD activity, both with isolated components and in
cells, so reducing HIF levels, leading to enhanced proliferation of
astrocytes21. However, the effect of (R)-2HG on PHD2 activity
and its potential relation to cancer remain controversial11,13,15,21.
The consensus catalytic mechanism for 2OG dependent
oxygenases proceeds via formation of an enzyme–Fe(II)–2OG–
substrate complex that binds dioxygen; subsequent oxidative
decarboxylation of 2OG yields succinate and carbon dioxide and
a reactive Fe(IV)–oxo intermediate, which performs the two-
electron substrate oxidation (Fig. 1, refs 22,23). Koivunen et al.21
have proposed that 2OG can be formed enzymatically in the
PHD2 active site as a product of (R)-2HG, but not (S)-2HG,
oxidation, and suggested that this occurs via an Fe(III)–
superoxide intermediate. While prime substrate C-H cleavage by
such intermediates has precedent in some non-haem iron
oxygenases24, C-H cleavage in a co-substrate is unprecedented
in 2OG oxygenase catalysis and in earlier work we did not
observe that 2HG can substitute for 2OG under our standard
assay conditions14.
Here we report investigations on the mechanism of the
apparent activation of PHDs by (R)-2HG and the origin of the
2HG conversion to 2OG. We show that conversion of 2HG to
2OG occurs non-enzymatically in a manner enabled by
biologically relevant reducing agents including L-ascorbate and
the reduced form of L-glutathione. The level of 2OG is sufficient
to support catalysis by PHD2, and at least one other human 2OG
oxygenase.
Results
Studies on the mechanisms of 2HG-promoted PHD2 catalysis.
To investigate the mechanism by which PHD activity is enabled
by the presence of 2HG, MALDI-TOF-MS (matrix assisted laser
desorption ionization-time of flight-mass spectrometry) based
assays were performed using a peptide fragment of the HIF-1a
C-terminal oxygen-dependent degradation domain (HIF-1a556–574,
hereafter CODD) and recombinant PHD2181–426 (hereafter
PHD2). In contrast to Koivunen et al.21, when substituting
300 mM 2OG for 5mM 2HG in our standard steady-state assay
conditions (4 mM PHD2, 200 mM CODD; Supplementary
Table 1), we did not observe any CODD hydroxylation after
short incubation times (up to 2 h, limit of detection:B3% CODD
hydroxylation). CODD hydroxylation was observed, however,
with longer incubation times (20 h) (Fig. 2c,d) in the presence of
both (R)- and (S)-2HG.
2OG oxygenase catalysis is often stimulated in vitro by
L-ascorbate or other reducing agents25–27. L-ascorbate is
required for PHD2 activity14,25,28, and is a standard component
in PHD2 reaction incubations21,29 (Supplementary Table 1).
We found that, under the steady-state conditions described
above, the extent of PHD2/2HG-mediated CODD hydroxylation
was dependent on L-ascorbate concentration; 20% CODD
hydroxylation was observed in the presence of 10mM
L-ascorbate (Fig. 2c,d), B4–7% CODD hydroxylation was
observed in the presence of lower, possibly more physiologically
relevant levels of L-ascorbate (0.1–0.3mM, Supplementary
Fig. 1a,b)30. L-Glutathione (thiol form, GSH) is a biologically
important antioxidant that plays a role in cellular protection
against oxidative stress31. We found that GSH was also able to
promote PHD2/2HG-mediated CODD hydroxylation, albeit
at higher concentrations than L-ascorbate (Fig. 2c,d). This
observation is consistent with the reduced ability of GSH to
stimulate 2OG-enabled PHD2 catalysis in vitro28.
To confirm 2HG-mediated prolyl-hydroxylation of CODD,
amino acid analyses were performed; trans-4-hydroxylated pro-
line was detected in hydrolysed PHD2/CODD assay mixtures
where the assay was conducted in the presence of either (R)- or
(S)-2HG (Fig. 2e,f). To test whether CODD hydroxylation was a
product of catalysis, rather than a result of non specific oxidation
by reactive oxidizing species (ROS) ‘leaking’ from the enzyme
active site, the Fe(II)/2HG/L-ascorbate/CODD assay mixture was
incubated with 0–100mM H2O2 instead of PHD2. A þ 16Da
mass shift in the CODD MALDI-TOF-MS spectra was not
observed under these conditions.
Studies on the binding of 2HG to PHD2. We were intrigued by
the differences in our results when compared with those of
Koivunen et al.21, including the incubation time required for
CODD hydroxylation to be observed, the apparent dependence
on the presence of reducing agent, and our observation that in the
presence of L-ascorbate no significant difference in the extent of
CODD hydroxylation was seen when using (S)- or (R)-2HG
(Fig. 2c,d). We therefore carried out investigations to understand
the nature of the 2HG/PHD2-mediated CODD hydroxylation,
including the possibility of (R)-2HG oxidation being catalysed by
PHD2, as proposed21.
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To investigate whether (R)- and (S)-2HG bind to the catalytic
domain of PHD2, biophysical techniques were employed. First,
we employed an NMR assay that measures displacement of 2OG
from the PHD2–Zn(II)–2OG complex (Zn(II) is a catalytically
inactive substitute for Fe(II))32. Previous studies indicated very
strong binding of 2OG to PHD2 (Kd¼ 1 mM), which was not
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Figure 2 | PHD2/2HG catalysis is enabled by reducing agents. Samples containing 4mM PHD2 (prolyl hydroxylase domain 2), 200mM C-terminal
oxygen dependent degradation domain (CODD) peptide, 5mM (R)- or (S)-2HG, 50mM Fe(II), 0/0.5/4/10mM L-ascorbate in Hepes 50mM pH 7.5
were incubated for 20 h (37 C) and then analysed by MALDI-TOF-MS or subjected to amino acid analysis. Error bars represent s.d. of the mean of
triplicate assays. 2OG (2-oxoglutarate) control incubations contained 300 mM 2OG instead of 2HG. (a) The PHD2-catalysed reaction. (b) Typical
MALDI-TOF-MS spectra of CODD-OH (upper) and CODD (lower). (c) Dependence of PHD2/(R)-2HG-catalysed CODD hydroxylation on L-ascorbate
and GSH (glutathione). (d) Dependence of PHD2/(S)-2HG-catalysed CODD hydroxylation reaction on L-ascorbate and GSH. (e,f) Amino acid analysis
results (A: 2HG, Fe(II), L-ascorbate; B: CODD, 2HG, Fe(II), L-ascorbate; C: PHD2, 2HG, Fe(II), L-ascorbate; D: PHD2, CODD, 2HG, Fe(II), L-ascorbate;
E: standard containing trans-4-hydroxyproline amino acid).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4423 ARTICLE
NATURE COMMUNICATIONS | 5:3423 | DOI: 10.1038/ncomms4423 | www.nature.com/naturecommunications 3
& 2014 Macmillan Publishers Limited. All rights reserved.
dependent on the presence of the prime substrate33. The NMR
results showed that both (R)- and (S)-2HG exhibit very
weak binding to PHD2 (determined Kd41mM and 40.6mM
respectively, Supplementary Fig. 2). Next, we used UV–vis
spectroscopy to probe for the formation of a metal-to-ligand
charge transfer feature: the anaerobic PHD2–Fe(II)–2OG
complex absorbs at 530 nm25; however, addition of (R)- or
(S)-2HG to PHD2–Fe(II) under anaerobic conditions did not
result in the formation of any observable metal-to-ligand charge
transfer feature (Supplementary Fig. 3). This suggests either the
absence of 2HG binding within limits of detection, or significant
differences in the interaction of 2HG with the active site metal
compared with 2OG. We then conducted non-denaturing MS
experiments to look for stable complex formation in the presence
and absence of CODD prime substrate (Supplementary Fig. 4)34.
(R)-2HG was not observed to bind to PHD2–Fe(II) by non-
denaturing MS (in contrast with 2OG), either in the absence
or presence of CODD, nor was there evidence for CODD
hydroxylation on analysis of PHD2–Fe(II)–(R)-2HG–CODD as
there was in the presence of 2OG. Overall, we were unable to find
any evidence for efficient 2HG binding to PHD2.
We next considered the possibility of 2OG contamination of
commercial batches of (R)- and (S)-2HG as a source of 2OG to
elicit CODD hydroxylation. NMR and liquid chromatography-
mass spectrometry (LC-MS) analyses revealed up to 0.02% (by
molarity) 2OG in almost all batches (three out of four)
of commercially purchased (R)-2HG, but not (S)-2HG
(4 batches), which is equivalent to 1 mM 2OG in 5mM (R)-
2HG (as used in standard assay conditions) (Supplementary
Fig. 5). 1 mM 2OG and 5mM (R)-2HG support similar degrees of
CODD hydroxylation, detectable under single turnover condi-
tions (Supplementary Fig. 1c). We further subjected (R)-2HG to
high-pressure liquid chromatography (HPLC) to remove
2OG contamination, then re-determined the IC50 values of both
(R)- and (S)-2HG (Supplementary Fig. 6); consistent with our
previous work14, we found that (R)- and (S)-2HG are both very
weak inhibitors of PHD2 (IC50 values are 23mM and 6mM for
(R)- and (S)-2HG, respectively). Thus, the low levels of CODD
hydroxylation observed in the absence of L-ascorbate (Fig. 2c,d)
may reflect the presence of contaminating 2OG in commercial
(R)-2HG samples, and may also reflect differences in (R)- and
(S)-2HG inhibition activities.
Reducing agent and iron promote non-enzymatic 2HG
oxidation. Given the apparent ability of reducing agents to pro-
mote 2HG-mediated CODD hydroxylation (Fig. 2c,d), we used
an antibody based assay, which gives a CODD-OH specific
fluorescent signal35, to investigate the conditions required for
CODD hydroxylation and to verify the sensitivity of our
MS-based assay. Interestingly, we found that when PHD2/
CODD were added after a 20 h preincubation of a mixture of
(R)- or (S)-2HG, Fe(II) and L-ascorbate, a fluorescence signal was
observed (indicative of CODD hydroxylation) after just 10min of
enzymatic activity. Fluorescence was greater in the samples
containing L-ascorbate, and there was no difference between
the two 2HG enantiomers (Supplementary Fig. 7). This result
suggested that during the course of the preincubation 2HG was
oxidized non-enzymatically to 2OG, to a level sufficient to
support PHD catalysis. We therefore considered it possible that
the mechanism of PHD2/2HG-mediated CODD hydroxylation
was via non-enzymatic 2HG oxidation to 2OG followed by
PHD2/2OG mediated CODD hydroxylation.
As reducing agents promote 2HG-mediated CODD hydroxyla-
tion (Fig. 2c,d), we investigated whether they are necessary for non-
enzymatic conversion of 2HG to 2OG. Mixtures of (R)- or (S)-2HG
with Fe(II) and different concentrations of L-ascorbate/GSH were
incubated for 20 h (37 C). 2OG formation was detected by LC-MS,
and was observed in the samples containing L-ascorbate and GSH,
without discrimination between (R)- or (S)-2HG (Fig. 3). Substitut-
ing with oxidized forms of L-ascorbate and glutathione (dehydroas-
corbate and GSSG) resulted in little or no 2OG formation (limited
2OG formation observed in the presence of dehydroascorbate could
be due to its partial reduction to L-ascorbate under the assay
conditions) (Fig. 3c,d). Reducing agents can therefore promote the
non-enzymatic oxidation of 2HG to 2OG.
We investigated the Fe(II)-dependence of non-enzymatic
conversion of 2HG to 2OG and found that ascorbate- and
glutathione-mediated 2HG oxidation requires the presence of
either Fe(II) or Fe(III) (Supplementary Figs 8 and 9). The level of
2OG produced (detected by LC-MS) was dependent on the
concentration of iron. We also investigated whether other
transition metals could substitute for Fe(II)/Fe(III) in this
reaction, and found that metals such as Zn(II), Mn(II), Co(II),
Ni(II) and Cu(II) did not promote 2OG formation. NMR studies
were performed to confirm that non-enzymatic oxidation of
2HG to 2OG is Fe(II)/(III)- and reducing agent-dependent
(Supplementary Fig. 9). Consistent with the LC-MS results, the
non-enzymatic conversion of 2HG to 2OG was observed, which
was promoted by the presence of both L-ascorbate and Fe(II)
(Fig. 4a). The time course of the reaction was investigated by
NMR and showed a linear increase in 2OG generation over 20 h
(Fig. 4b). Although, an excess of L-ascorbate/GSH relative to iron
was found to be required to effectively enable the non-enzymatic
reaction (Fig. 3c,d), physiologically relevant levels of these
reducing agents30,36 are able to promote 2OG formation to
levels that sustain CODD hydroxylation (Fig. 2c,d). Notably,
low amounts of 2OG were also observed after incubation of
2HG and 10mM L-ascorbate when no Fe(II) was added (Fig. 4a),
which could be due to trace Fe(II) contamination present in
reaction components including ascorbate and H2O, as revealed
by inductively coupled plasma-mass spectrometry (ICP-MS)
analyses (at least B1 mM Fe(II)/Fe(III), Supplementary Table 2).
H2O2 and iron promote non-enzymatic 2HG oxidation. In
addition to 2OG, the NMR assays revealed formation of succinate
and another oxidation product, which on the basis of NMR and
MS studies was assigned as succinic semialdehyde (SSA) by
comparison with a synthetic standard (Fig. 4d, Supplementary
Figs 10 and 11) and LC-MS assays (Supplementary Fig. 12).
Fenton type chemistry is viable for a-hydroxyacid oxidation37;
therefore, the possibility of H2O2-mediated 2HG oxidation was
studied. It was found that 2HG oxidation is enabled by H2O2 to
give 2OG, SSA and succinate, and that Fe(II) or Fe(III) are
required for this transformation (Fig. 5, Supplementary Fig. 13).
Interestingly, while 2HG oxidation is relatively slow under the
conditions of the Fe(II)/L-ascorbate system (16–20 h or more), the
H2O2-driven reaction is substantially faster (2OG formation was
apparent by NMR after 1 h of incubation) (Supplementary
Fig. 14). The observed ratio between 2OG and SSA was found
to be dependent on the amount of H2O2 added (Supplementary
Figs 15 and 16). To investigate whether SSA is the product of
further oxidation of 2OG, 2OG oxidation under Fe(II)/
L-ascorbate and Fe(II)/H2O2 conditions was also studied.
2OG was found to be oxidized to succinate, but not to
detectable levels of SSA (Supplementary Figs 17 and 18),
indicating that SSA formation occurs via an alternative 2HG
oxidative pathway. Detectable SSA oxidation to succinate was not
observed under these conditions (Supplementary Fig. 14).
Therefore the 2HG oxidation reaction most likely proceeds via
iron-complex formation. Overall, the results reveal that 2HG is
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4423
4 NATURE COMMUNICATIONS | 5:3423 |DOI: 10.1038/ncomms4423 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
oxidized to 2OG and SSA via (at least) two alternative oxidative
pathways, and the ratio of the products depends on the amount of
H2O2 present.
To investigate the role of iron in the observed peroxide driven
reaction, we performed stopped-flow UV–vis spectroscopy
studies. Transient species absorbing at 240–340 nm, which likely
represent different iron oxidation states38, were observed during
the H2O2-mediated 2HG oxidation (where the Fe(II)/(R)-2HG
mixture was rapidly mixed with H2O2, Supplementary Figs 19
and 20). The formation and degradation of these species occurred
over 5min with the maximum time of their accumulation
dependent on the H2O2 concentration, consistent with the NMR
2HG oxidation time course studies (Supplementary Fig. 14),
which supports the proposal of iron-mediated conversion of
2HG to 2OG.
2HG-enabled promotion of catalysis by other 2OG oxygenases.
2OG oxygenases can produce ROS as a result of incomplete
catalytic cycles, which we envisaged could stimulate the observed
H2O2-dependent 2HG oxidation27. To investigate this possibility,
we studied formation of succinate and 2OG (from 2HG) in the
presence of PHD2, with and without CODD substrate (Fig. 4c).
The total combined concentrations of 2OG and succinate were
not increased in the presence of PHD2, suggesting against 2HG
oxidation due to ROS production from the PHD2 active site.
Owing to consumption of 2OG (produced from 2HG) in the
enzymatic reaction, levels of succinate were higher in the presence
of PHD2 supporting the proposal that the non-enzymatic
oxidation of 2HG occurs at a level sufficient to support PHD2
catalysis.
Given the reported ability of (R)-2HG to activate the PHDs
but not other 2OG oxygenases21, we investigated whether
the observed L-ascorbate-dependent 2HG to 2OG conversion
is sufficient to support catalysis by oxygenases other than
PHD2. We carried out activity assays with 2HG and L-ascorbate
for other human 2OG oxygenases including BBOX1
(g-butyrobetaine oxygenase, which catalyses the final step in
L-carnitine biosynthesis), FIH and the catalytic domain of
KDM4A (JMJD2A), an Ne-methyl lysine demethylase. NMR
studies on BBOX1 showed that in the absence of 2OG, 2HG
addition enables carnitine formation from g-butyrobetaine (GBB)
(Fig. 6). The observed carnitine levels were higher in the case of
(R)-2HG, which is consistent with its lower inhibition potency
compared with (S)-2HG for BBOX1 (IC50 values are 13.2mM and
142 mM, for (R)-2HG and (S)-2HG, respectively)14. Consistent
with the fluorescence-based assays on PHD2, addition of BBOX1
to a 2HG/Fe(II)/L-ascorbate mixture, reacted prior to the enzyme-
incubation at 37 C for 20 h, leads to higher levels of carnitine
formation (Fig. 6). As for PHD2 this observation implies that the
conversion of 2HG to 2OG is non-enzymatic, with 2OG being
formed under the assay conditions. The assays with FIH and
KDM4A did not reveal any 2HG-enabled enzyme catalysis at the
same concentrations of 2HG/Fe(II)/L-ascorbate (for which
activity was observed for PHD2 and BBOX1), as determined by
MS assays. These observations can be rationalized by the 2HG-
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Figure 3 | 2HG conversion to 2OG is non-enzymatic. (a,b) LC-MS chromatograms showing 2OG formation under non-enzymatic conditions in the
presence of GSH (glutathione). (c,d) Amounts of 2OG formed with different reducing agents. Error bars represent s.d. of the mean of triplicate assays.
The reaction mixture was incubated for 20 h (37 C) and contained 5mM (R)- or (S)-2HG, 50mM Fe(II), reducing agent (from bottom to top in (a,b): no
reducing agent; 0.5mM; 4mM; 10mM reducing agent). All panels in one stack in (a,b) have the same range of ion intensity (0–6.5  105).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4423 ARTICLE
NATURE COMMUNICATIONS | 5:3423 | DOI: 10.1038/ncomms4423 | www.nature.com/naturecommunications 5
& 2014 Macmillan Publishers Limited. All rights reserved.
mediated inhibition of FIH and KDM4A catalysis, and/or by the
increased sensitivity of FIH (relative to PHD2) to ROS, including
H2O2, as reported14,21,39.
As SSA was observed as a co-product of 2HG oxidation, we
studied its influence on 2OG-dependent oxygenases such as
PHD2, FIH, KDM4A and BBOX1 (to the extent of our knowledge
no data on SSA inhibition of 2OG oxygenases have been
reported). SSA caused weak inhibition of all these enzymes (IC50
values are 4.5mM, 2.9mM, 2.8mM and 267 mM for FIH, PHD2,
KDM4A and BBOX1, respectively (Supplementary Fig. 21)).
Discussion
Overall, our results clearly demonstrate that the non-enzymatic
conversion of 2HG to 2OG can occur. The reaction is promoted
by the combination of Fe(II)/Fe(III) and biologically relevant
reducing agents such as L-ascorbate and GSH as well as by H2O2.
The 2OG levels produced by non-enzymatic oxidation under our
standard steady-state assay conditions are sufficient to support
in vitro catalysis by some 2OG oxygenases (PHD2 and BBOX1),
but not others (FIH and KDM4A). Although it is not possible to
isolate and characterize these reactions within cells, the non-
enzymatic conversion of 2HG to 2OG can occur in vitro with
physiologically relevant concentrations of Fe(II/III)/reducing
agents. We propose that the conditions used by Koivunen
et al.21 likely resulted in non-enzymatic 2HG conversion to 2OG,
and that contamination of 2HG with 2OG in commercial samples
could also contribute to the 2HG-mediated CODD hydroxylation
observed previously and in this study (Supplementary Fig. 1c).
Although we cannot rule out that it occurs at levels below our
limits of detection, we have accrued no evidence for direct 2OG
oxygenase catalysed 2HG oxidation; indeed, biophysical studies
imply that 2HG binds very weakly to PHD2. In addition,
non-enzymatic oxidation should occur without discrimination
between enantiomers, which is in accord with our observations.
The apparent preference for PHD2 catalysis to proceed in the
presence of (R)- rather than (S)-2HG observed by Koivunen et al.
can be rationalized by the observation that the (S) enantiomer is a
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better PHD2 inhibitor14 and/or by contamination of some
commercial (R)-2HG batches by 2OG. Similarly with BBOX1,
the increased activity with (R)-, rather than (S)-2HG, is consistent
with the higher inhibition potency for the (S)-enantiomer14. The
lack of observed 2HG catalysis with KDM4A and FIH may be due
to the relatively stronger inhibition of the former by both (R)- and
(S)-2HG, and the sensitivity of FIH to ROS, including H2O2
(refs 14,39). Thus, even though the conversion of 2HG to 2OG is,
at least predominantly, non-enzymatic and not enantioselective,
the results of the incubation of 2HG with enzymes can appear
enantioselective in a condition-dependent manner.
The exact mechanisms (likely more than one) of the non-
enzymatic oxidation of 2HG are unclear, but probably proceed
via iron-complexed ROS40–42. Higher rates of reaction were
observed with H2O2 replacing L-ascorbate, suggesting the role
of L-ascorbate/GSH is to generate ROS, though the exact
mechanisms in operation are likely condition-dependent40.
Further work can focus on whether the non-enzymatic
conversion of 2HG to 2OG is of physiological relevance. Given
the complexity of 2HG/2OG/TCA cycle metabolism, it is difficult
to distinguish between non-enzyme and enzyme-catalysed
reactions in cells (Fig. 7)1. However, it is well-established that
many proteins undergo non-enzymatic oxidative modifications43.
As indicated in Fig. 7, it is possible that non-enzymatic reactions
may augment the network of identified enzyme-catalysed
reactions related to 2HG. The concentrations of the reducing
agents at which we observed significant conversion in vitro are
probably above those for individual reducing agents in cells30.
However, taking into account the total cellular concentration of
reducing agents capable to promote 2HG oxidation we cannot
exclude the possibility of them being sufficient to promote the
reaction. Although our in vitro observations indicate that supra-
physiological levels of free Fe(II)/Fe(III) (45 mM)36 are required
for significant levels of 2OG to be formed from 2HG, it is possible
that 2HG oxidation may be mediated by complexed iron. Given
that non-enzymatic 2HG oxidation is promoted by H2O2 and
likely some other ROS, this reaction may be relatively more
important under conditions of oxidative stress, mediated by
elevated ROS, such as that occurring in hypoxia44–47 or in
environments of high H2O2 concentration, for example, as
occurring in peroxisomes.
Interestingly, recent work indicates reduction of antioxidant
concentrations in IDH-mutated mice12. It is thus possible that
non-enzymatic Fenton-type chemistry including 2HG/2OG and
related metabolites may be involved in the regulation of ROS
levels. Indeed, although IDH1/2 mutations have been identified
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in many cancers5, the mechanisms by which they relate to
tumorigenesis are unclear. Although, the balance of current
evidence suggests that direct inhibition of the HIF hydroxylases
by (R)-2HG is probably not physiologically important12,14,15, the
inhibition of chromatin-modifying (or other) 2OG oxygenases by
(R)-2HG with pathophysical consequences remains plausible14–
16,48. It is also proposed that ‘gain-of-function’ IDH mutations
may result in depletion of antioxidants including L-ascorbate and
GSH, together with perturbation of the NADPþ /NADPH ratio,
leading to physiologically relevant oxidative stresses5. The non-
enzymatic chemistry identified here may contribute to the
development of such stresses.
SSA is a metabolite produced by oxidation of g-aminobutyric
acid (GABA)49 (Fig. 7). A deficiency in SSA dehydrogenase
results from genetic disorders leading to accumulation of SSA in
cells where it cannot be further oxidized to succinic acid and
subsequently utilized in the TCA cycle50. The observation that
SSA and succinic acid can be concomitantly produced with 2OG
by 2HG oxidation is of interest. The reactive nature of SSA
suggests that a potential role for it in cancer metabolism merits
investigation. Given that we found that the ratio of 2OG to SSA
observed was condition-dependent, it will also be of interest to
investigate whether SSA can be detected or its levels vary in cells
under conditions of redox stress such as in tumour cells or in
highly oxidizing environments such as peroxisomes. It is also
notable that in some cases the inhibition potency of SSA for the
studied enzymes was higher than for (R)-2HG, raising the
possibility that it might inhibit enzymes in cells.
Our results have consequence for the interpretation of the
important cellular observations of Koivunen et al.21 Both HIF-1a
and HIF-2a levels were reported to be lower in mid-passage
astrocyte cells, in which mutant IDH1 R132H protein was
present, compared with wild-type cells. Our results imply that
this is unlikely to be due to direct use of (R)-2HG as a PHD2 co-
substrate. Although it does not rationalize the reported resistance
of the IDH1 mutant cells to the NOG (N-oxalyl glycine)
precursor DMOG (dimethyloxalyl glycine)21, it is possible that
the observed effects on HIF-a levels in the astrocyte cells were in
part a manifestation of the effect of increased 2HG levels on
chromatin-modifying enzymes, including the JmjC demethylases
and TET enzymes. The proposal that some of the observed effects
on the IDH1 mutant on HIF-a might be mediated via ‘epigenetic
processes’ may relate to the observation that HIF-a levels were
reported to normalize in later passages (more than passage 20)
despite continued production of the mutant IDH1 enzyme and
(R)-2HG. We hope that our results will stimulate further work
on the cellular mechanism by which 2HG stimulates PHD
activity.
Methods
Materials. (R)- and (S)-2-hydroxyglutaric acid disodium salts were from
Sigma-Aldrich, UK. The HIF-1a(556–574) CODD peptide, where Met residues in
the initial HIF-1a sequence were replaced with Ala, (DLDLEALAPYIPADDDFQL)
and HIF-1a(788–822) CAD peptide (DESGLPQLTSYDCEVNAPIQGSRNLLQG
EELLRAL) were from GL Biochem (Shanghai) Ltd, China. H3K9me3 (ARK(me3)
STGGK) was synthesized as described51. Recombinant constructs of catalytic
domain of KDM4A (residues 1–359), PHD2 (residues 181–426) and full-length
FIH were produced as N-terminally His6-tagged protein in Escherichia coli
BL21(DE3) cells and purified by Ni-affinity, size-exclusion and cation exchange
chromatography as described52–54. BBOX1 was expressed and purified as described
by Leung et al.55
Enzymatic assays. PHD2, FIH and KDM4A assays were performed at 37 C as
reported14. The substrate for PHD2 was the HIF-1a(556–574) CODD 19-mer
peptide fragment, wherein the Met residues of the human HIF-1a sequence were
substituted for Ala residues to avoid non specific Met oxidation to give a sulfoxide
(þ 16Da). The substrate for FIH was the HIF-1a(788–822) CAD 35-mer peptide
fragment. The substrate for KDM4A was the H3K9me3 peptide. The conditions are
described in the Supplementary Table 3. Samples were analysed using a Waters
Micromass MALDI micro MX mass spectrometer (Micromass UK Ltd.,
Manchester, UK) in reflectron mode with flight tube voltage at 12 kV and reflectron
voltage at 5.2 kV. Data were analysed using MassLynx version 4.1. BBOX1 activity
assays were performed by NMR. Unless otherwise stated the standard assay
mixture contained 100 nM BBOX1, 100 mM GBB (g-butyrobetaine), 4mM
L-ascorbate, 50 mM (NH4)2Fe(SO4)2 and 80mM KCl in 50mM Tris-d11 (pH 7.5)
containing 10% D2O.
SSA inhibition studies were performed by MALDI-TOF-MS and NMR (human
BBOX1) using the described conditions14. Inhibition of human BBOX1 by SSA was
measured by observing carnitine formation by 1H NMR (Bruker Avance 700).
Control reaction mixtures contained 40 mM 2-oxoglutarate disodium salt, 40 mM
g-butyrobetaine hydrochloride, 40 mM ammonium (NH4)2Fe(SO4)2, 500 mM
L-ascorbate, 40mM KCl and 10% D2O in 50mM pH 7.5 Tris-d11. Reactions were
initiated by addition of human BBOX1 (final concentration 100 nM), the first 1H
NMR spectrum was acquired after 10min.
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LC-MS experiments. For LC-MS assays, reaction mixtures typically contained
5mM (R)- or (S)-2HG, 50mM (NH4)2Fe(SO4)2 and variable concentrations (0–
10mM) L-ascorbate/GSH prepared in 50mM Hepes (pH 7.5), and were incubated
for 20 h (37 C). 2OG production was subsequently measured. Chromatographic
separation was performed at 50 C using a Waters ACQUITY BEH Amide 1.7 mm
2.1 100mm column and a Waters ACQUITYTM ultra-performance liquid
chromatography system (Waters Corp., Milford, MA, USA). The following eluents
were used: mobile phase A: 10% H2O, 90% acetonitrile (v/v), 10mM ammonium
formate; mobile phase B: 50% H2O, 50% acetonitrile (v/v), 10mM ammonium
formate. The elution gradient was 0–10.0min linear from 10–30% B, and
10.0–12.0min at 10% B for re-equilibration of the column. A constant flow rate
of 0.4mlmin1 was used. This was directly coupled to a Waters Quattro micro
(Micromass UK Ltd) triple quadrupole mass spectrometer in negative ionization
mode. The desolvation temperature was set to 250 C and the source temperature
to 120 C.
NMR experiments. NMR experiments were conducted at 298 K using a Bruker
Avance III 700MHz spectrometer equipped with a 5mm inverse TCI cryoprobe
and 3mm diameter MATCH NMR tubes (Bruker). Water suppression was
achieved by the excitation sculpting method using a 2ms 180 degree selective
Sinc1.1000 pulse at the H2O frequency. Typical experimental parameters were as
follows: number of transients 256, relaxation delay 2 s. Unless otherwise stated
all samples were 400 ml final volume, consisting of 90% H2O and 10% D2O
with the following concentrations in the reaction mixture: 5mM 2HG, 50 mM
(NH4)2Fe(SO4)2 and 10mM L-ascorbate. The non-enzymatic reaction was started
by addition of hydrogen peroxide with 5mM as standard final concentration and
then monitored for 2 h by 1H NMR at 298 K.
The CPMG (Carr–Purcell–Meiboom–Gill) displacement experiments were
conducted using the AV700 instrument and 3mm MATCH NMR tubes32. The
PROJECT-CPMG sequence (90x–[t–180y–t–90y–t–180y–t]n–acq) was applied
as described by Aguilar et al.56 Typical experimental parameters were as follows:
total echo time 48ms (t¼ 2ms, n¼ 6), acquisition time 2.94 s, relaxation delay 2 s
and number of transients 128. Water suppression was achieved by presaturation.
UV–vis spectroscopy experiments. Absorption spectra were acquired using a
Cary Varian 4000 UV–vis spectrophotometer at 22 C with 0.1mM PHD2, 0.1mM
Fe(II) and 0.5mM 2OG or (R)/(S)-2HG in deoxygenated 50mM Hepes (pH 7.5).
The buffer and enzyme were deoxygenated according to the described procedure22.
All other solutions were prepared in an anaerobic glove box (Belle Ltd., UK).
Non-denaturing ESI-MS experiments. Non-denaturing ESI-MS experiments
were performed as described57. PHD2 was buffer-exchanged into 15mM
ammonium acetate (pH 7.5). Data were analysed using MassLynx 4.0.
Amino acid analysis. Amino acid analysis was performed as previously
described58. An extracted ion chromatogram was created using m/z value
corresponding to AQC-derivatized hydroxyproline (304±0.2Da). Three
chromatograms were acquired for every sample. The limit of detection for
the method was determined to be B1 pmol ml 1.
Stopped-flow UV–vis spectroscopy experiments. Solutions of 10mM (R)-2HG,
0.2mM Fe(II) were prepared in Milli-Q water and rapidly mixed with 2mM H2O2
at 1:1 ratio in a stopped-flow apparatus (Applied Photophysics, Leatherhead, UK).
Subsequent analysis used an SX20 stopped-flow spectrometer and spectra were
recorded over time up to 500 s using a photodiode array detector. All assays were
performed at least in triplicate.
Synthesis of SSA. SSA was prepared from methyl 4,4-dimethoxybutyrate
(Sigma-Aldrich). The starting material (100mg) was dissolved in 5ml of
tetrahydrofurane and treated with 3ml of 1M lithium hydroxide. The reaction
mixture was stirred overnight and then tetrahydrofurane was removed in vacuo.
The water phase was acidified with concentrated HCl and stirred for a further 6 h.
The solution was concentrated to 1ml in vacuo and purified on HPLC (reverse
phase column, gradient 10% of B in 15min where A: 0.05% TFA in H2O, B: 0.1%
TFA in acetonitrile, retention time 9min). Fractions containing the product were
freeze-dried to yield SSA as an off-white oil.
1H NMR (500MHz, D2O) d p.p.m. 5.00 (t, J¼ 5.5), 2.40 (t, J¼ 7.5), 1.82
(dt, J1¼ 7.5, J2¼ 5.5); 13C NMR (125MHz, D2O) d p.p.m. 177.5, 89.1, 31.9, 28.8.
LC-MS analysis retention time is 1.15min (Waters ACQUITY BEH Amide 1.7 mm
2.1 100mm column, mobile phase A: 10% H2O, 90% acetonitrile (v/v), 10mM
ammonium formate; mobile phase B: 50% H2O, 50% acetonitrile (v/v), 10mM
ammonium formate), mass—101.2 (negative ion mode).
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